Compare Quest Diagnostics Inc (DGX) vs MasTec Inc (MTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs MasTec Inc — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while MasTec Inc trades at $364.95 (market cap $28.85B). The key difference: MasTec Inc is the larger of the two by market cap, and Quest Diagnostics Inc pays a 1.67% dividend while MasTec Inc pays none. Which is the better fit depends on your goals.
| DGX | MTZ | |
|---|---|---|
Market Cap | $22.80B | $28.85B |
Sector | Health | Technology |
52-Week High | $216.02 | $437.51 |
52-Week Low | $166.42 | $171.92 |
Enterprise Value | $28.82B | $31.60B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
MasTec (MTZ) trades at $360.21, down 3.4% on the day, with a bearish technical signal despite strong fundamental performance. The company recently announced a $1.65 billion acquisition of The Superior Group to expand its data center infrastructure capabilities, boosting its position in AI-driven markets. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 showing 34% revenue growth and 73% adjusted EBITDA growth, supported by a record $20.3 billion backlog.
Wall Street maintains strong bullish sentiment with 89% buy ratings and a $481.77 consensus price target suggesting 34% upside potential. Key risks include integration challenges from the large acquisition and premium valuation metrics. The stock's current weakness presents a potential buying opportunity for investors bullish on infrastructure spending trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
